South America Pneumococcal Vaccines
At cognitive, a dedicated team has worked on this report. You can initiate the discussion via Book an appointment.
Our research analyst works closely with South America Pneumococcal Vaccines market experts to validate gathered data.
Historical data 2022–2025. Base Year: 2025. Forecast: 2026–2034.
Unique identification number from Cognitive's database.
Athenaeum Dashboard, PDF, Excel, MS Word, Cloud Access and AI Assistant.
8th Edition published by Cognitive Market Research.
| Data Timeline | Historical Data: 2022-2025 | Base Year: 2025 | Forecast Period: 2026-2034 |
|---|---|
| Vaccine Type Segment Analysis | Pneumococcal Polysaccharide Vaccines, Pneumococcal Conjugate Vaccines |
| Product Type Segment Analysis | Pneumovax 23, Synflorix, Prevnar 13, Others |
| Sector Segment Analysis | Public, Private |
|---|---|
| Distribution Channel Segment Analysis | Pharmacies, Community clinics, Public Health agencies, Others |
| Country Analysis | Brazil, Argentina, Colombia, Peru, Chile, Rest of South America |
Share your contact details to receive free updated sample copy/pages of the recently published edition of South America Pneumococcal Vaccines Market Report 2025.
According to Cognitive Market Research, the South America Pneumococcal Vaccine Market Size was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.
| Market Size | 2021 (A) | 2025 (A) | 2033 (P) | CAGR |
|---|---|---|---|---|
| South America Pneumococcal Vaccines Market Size | xxxx | xxxx | xxxx |
South America Pneumococcal Vaccines Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
In South America, more than 70% of the 52 countries and territories have already introduced pneumococcal conjugate vaccines (PCVs) into their national immunization programs for infants. The pneumococcal disease burden remains high in adults, particularly among the elderly as the population is aging in several large countries in this region. The need to prevent the disease in older adults is increasing the importance of pneumococcal vaccines in the region, leading to the growth of the market.
(Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518830/)
Read a Detailed Qualitative analysis of the above report by requesting the free sample pages from Request for your Free Sample PDF/Online Access.
To sustain the increasing competition and attain new heights in providing healthcare services, companies are leveraging advancements in technology to innovate and launch new products to gain a competitive advantage. Companies are continuously investing in research and development activities to stay upgraded as per the changing consumer preferences, and market demand, and offer quality treatment options.
Top Companies Market Share in South America Pneumococcal Vaccines Industry: (In no particular order of Rank)
| Companies | 2022 (A) | 2023 (A) | 2024 (A) | 2025 (A) |
|---|---|---|---|---|
| Pfizer Inc. | xxxx | xxxx | xxxx | xxxx |
| GlaxoSmithKline plc | xxxx | xxxx | xxxx | xxxx |
| Merck & Co. Inc. | xxxx | xxxx | xxxx | xxxx |
| Serum Institute of India Pvt. Ltd | xxxx | xxxx | xxxx | xxxx |
| Biological E. Limited | xxxx | xxxx | xxxx | xxxx |
| Abbott | xxxx | xxxx | xxxx | xxxx |
| Sanofi Pasteur SA | xxxx | xxxx | xxxx | xxxx |
| Wyeth Pharmaceuticals LLC | xxxx | xxxx | xxxx | xxxx |
| Walvax Biotechnology Co. Ltd. | xxxx | xxxx | xxxx | xxxx |
| Sk Bioscience. | xxxx | xxxx | xxxx | xxxx |
| Panacea Biotec Limited. | xxxx | xxxx | xxxx | xxxx |
*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive)
Request Any Company Profile for Preview Purpose OR Data Validation!
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
The published report edition delivers South America Market size analysis from 2021 till the forecast period of 2033. We have included analysis of top performing countries such as (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America) and their Market segmentation by Vaccine Type, Product Type, Sector, Distribution Channel , etc. This will help you to understand detailed segment profile, revenue generation, growth patterns, trends, and differences among the each segments.
By Vaccine type, the market is dominated by Pneumococcal Conjugate Vaccines (PCV). These vaccines can protect children from Streptococcus pneumoniae, which is the most common cause of severe bacterial pneumonia among children. It is already been used in the national immunization program of 146 countries as of June 2020. PCV has demonstrated effectiveness in reducing the incidence and severity of pneumonia and other lower respiratory infections in children. PCVs are the vaccines that are generally recommended for infants younger than two years of age as Pneumococcal Polysaccharide Vaccines (PPSV) are comparatively less effective for this age group.
Note: The above Chart is for representative purposes and does not depict actual sales & statistics. You can request a free sample or purchase the full report access today!
Among all the product types, Prevenar 13 is reported to dominate the pneumococcal vaccine market. Prevenar 13 is a vaccine available as a suspension for injection that contains parts from 13 different types of the bacterium Streptococcus pneumoniae. It is normally used to protect children aged between six weeks and 17 years against invasive disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae. This vaccine helps the body make its antibodies which protect against such diseases. As the name goes, Prevenar 13 is only capable of protecting against disease caused by thirteen strains of Streptococcus pneumoniae bacteria included in the vaccine. Additionally, as per studies, Prevenar 13 led to an increase in antibody production following booster vaccinations.
Note: The above Chart is for representative purposes and does not depict actual sales & statistics. You can request a free sample or purchase the full report access today!
Based on distribution channels, the market is reported to be dominated by public health agencies. They have the largest hold on the purchases of vaccines made by organizations like GAVI, WHO, UNICEF, and others. These organizations purchase vaccines in bulk quantities and distribute them across the geographies.
GAVI-supported countries immunize more than 215 million children across 60 lower-income countries against pneumococcal disease in 2019.
In the same year, pneumococcal vaccine coverage in Gavi-supported countries was higher than the worldwide average of 49% in 2019.
(Source: https://www.gavi.org/types-support/vaccine-support/pneumococcal)
The Current Published report Editon on the website includes the following list of countries analysis whereas in case you looking to access any other country or states level data under South America then please revert us to access the exclusive South America Pneumococcal Vaccines industry report Edition.
The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!
The base years considered for all the estimations by analyzing trends and growth rate will help you gain an in-depth understanding of the conclusions provided in this report. This report also includes figures, graphs, pie charts, tables and bar graphs that explain the data analysis based on current trends at the country level as well as key regions. This research report also focuses on assessing factors such as profit, product price, capacity, production, supply demand market growth rate along with others to create a clear picture on the future prospects of this market.Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Global South America Pneumococcal Vaccines Market is witnessing significant growth in the near future.
In 2023, the Pneumococcal Polysaccharide Vaccines segment accounted for noticeable share of global South America Pneumococcal Vaccines Market and is projected to experience significant growth in the near future.
The Pneumovax 23 segment is expected to expand at the significant CAGR retaining position throughout the forecast period.
Some of the key companies Pfizer Inc. , Merck & Co. Inc. and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.
Research Analyst
LinkedIn | Profile | Book Appointment
Supriya Yadav is a dedicated market research professional with expertise in the aerospace and defence industry. At Cognitive Market Research, she focuses on delivering strategic insights into aviation advancements, defence technologies, and global security trends shaping the future of the sector.
Her research covers areas such as military modernization, commercial aviation growth, space exploration, and defence procurement strategies. With a strong analytical mindset and attention to technological evolution, Supriya provides data-driven intelligence that supports innovation, strategic planning, and informed decision-making within the aerospace and defence domain.
As a Research Analyst, I bring over two years of experience in market research, data analysis, and market estimation. I specialize in turning complex datasets into meaningful insights that help businesses identify opportunities, understand market dynamics, and make confident, growth-focused decisions.
My expertise spans across analyzing industry trends, forecasting market potential, mapping competitive landscapes, and studying consumer behavior to deliver actionable recommendations. With an MBA in Marketing and Finance, I combine strong analytical skills with strategic thinking, ensuring that every project I work on contributes real value to clients.
I am passionate about using research to uncover patterns, anticipate shifts, and deliver insights that drive measurable business impact. My goal is to continuously learn, innovate, and provide data-driven solutions that empower clients to succeed in a competitive environment.
Table of Content differs accordign to the user License selction. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section's Or chapter's from the report. Specific section's of report can be ordered at a discounted price. If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Vaccine Type | Pneumococcal Polysaccharide Vaccines, Pneumococcal Conjugate Vaccines |
| Product Type | Pneumovax 23, Synflorix, Prevnar 13, Others |
| Sector | Public, Private |
| Distribution Channel | Pharmacies, Community clinics, Public Health agencies, Others |
| List of Competitors | Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc., Serum Institute of India Pvt. Ltd, Biological E. Limited, Abbott, Sanofi Pasteur SA, Wyeth Pharmaceuticals LLC, Walvax Biotechnology Co. Ltd., Sk Bioscience., Panacea Biotec Limited. |
Chapter 1 2026 Geopolitical Outlook - South America Pneumococcal Vaccines Market Detailed Analysis
This chapter isn't just about technology; it’s about certainty. We show you how AI is being used in leading industries so you can apply those same 'High-Speed' and 'High-Accuracy' principles to your own market strategy
Chapter 2 AI's Impact on Market - Detailed Qualitative Analysis
This chapter will help you gain South America Market Analysis of South America Pneumococcal Vaccines. Further deep in this chapter, you will be able to review South America South America Pneumococcal Vaccines Market Split by various segments and Country Split.
Chapter 3 South America Market Analysis
Chapter 4 Brazil Market Analysis
Chapter 5 Argentina Market Analysis
Chapter 6 Colombia Market Analysis
Chapter 7 Peru Market Analysis
Chapter 8 Chile Market Analysis
Chapter 9 Rest of South America Market Analysis
This chapter provides an in-depth analysis of the market share among key competitors of South America Pneumococcal Vaccines. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 10 Competitor Analysis (Subject to Data Availability (Private Players))
(Subject to Data Availability (Private Players))
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 11 Qualitative Analysis (Subject to Data Availability)
Segmentation Vaccine Type Analysis 2019 -2031, will provide market size split by Vaccine Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Vaccine Type Analysis 2022 - 2034
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 13 Market Split by Product Type Analysis 2022 - 2034
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 14 Market Split by Sector Analysis 2022 - 2034
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 15 Market Split by Distribution Channel Analysis 2022 - 2034
Chapter 16 South America Pneumococcal Vaccines Price Trend Analysis
Chapter 17 South America Pneumococcal Vaccines Import/Export Analysis
Chapter 18 Gap Analysis
Chapter 19 Strategy Analysis
Chapter 20 Profitability and Gross Margin Analysis
Chapter 21 TAM Analysis
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global South America Pneumococcal Vaccines market
Chapter 22 Research Findings
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
Chapter 23 Research Methodology and Sources
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for our full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants your team direct access to our lead analysts for bespoke strategic consultation.